From Wikipedia, the free encyclopedia
|Source||Humanized (from mouse)|
|Target||scatter factor receptor kinase|
|Chemical and physical data|
|Molar mass||99.1 kg/mol|
|NY (what is this?)|
Onartuzumab is a humanized monoclonal antibody designed for the treatment of cancer.
Onartuzumab was developed by Genentech, Inc.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab" (PDF). American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|